摘要:
A novel antitumor substance BE-13793C or a pharmaceutically acceptable salt thereof, which is represented by the following formula: ##STR1## an anticancer agent comprising the novel substance or a pharmaceutically acceptable salt thereof, a method of producing the novel substance and a microorganism capable of producing the novel substance are disclosed.
摘要:
An antitumor substance BE-12406 or a pharmaceutically acceptable salt thereof, which is represented by the general formula ##STR1## and a method of producing the novel substance.
摘要:
A novel antitumor substance BE-13793C or a pharmaceutically acceptable salt thereof, which is represented by the following formula: ##STR1## an anticancer agent comprising the novel substance or a pharmaceutically acceptable salt thereof, a method of producing the novel substance and a microorganism Streptoverticillium FERM P-10489, capable of producing the novel substance are disclosed.
摘要翻译:一种新型抗肿瘤物质BE-13793C或其药学上可接受的盐,由下式表示:(*化学结构*)包含该新物质或其药学上可接受的盐的抗癌剂,该新物质的制备方法和 公开了能够生产该新物质的微生物Streptoverticillium FERM P-10489。
摘要:
A novel antitumor substance BE-13793C or a pharmaceutically acceptable salt thereof, which is represented by the following formula: ##STR1## an anticancer agent comprising the novel substance or a pharmaceutically acceptable salt thereof, a method of producing the novel substance and a microorganism capable of producing the novel substance are disclosed.
摘要:
This invention relates to 12,13-dihydro-6H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione derivatives represented by the following general formula, pharmaceutically acceptable salts thereof, a method for preparation thereof and a use thereof: ##STR1## [wherein R.sup.1 denotes a monosaccharide group having 5 to 7 carbon atoms, and the hydroxyl groups of this monosaccharide group can be replaced by the same or different 1 to 3 groups selected from the group consisting of a hydrogen atom, lower alkyl group, lower alkylcarbonyloxy group and lower alkoxy group.]
摘要:
This invention relates to 12,13-dihydro-6H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione derivatives represented by the following general formula, pharmaceutically acceptable salts thereof, a method for preparation thereof and a use thereof: ##STR1## [wherein R.sup.1 denotes a monosaccharide group having 5 to 7 carbon atoms, and the hydroxyl groups of this monosaccharide group can be replaced by the same or different 1 to 3 groups selected from the group consisting of a hydrogen atom, lower alkyl group, lower alkylcarbonyloxy group and lower alkoxy group.]
摘要:
The present invention relates to new stromelysin (human)-inhibitors, i.e., physiologically active substances BE-16627 represented by the general formula: ##STR1## wherein R represents a hydrogen atom or a methyl group, or pharmaceutically acceptable salts thereof, a process for the production and use thereof, and a microorganism producing the substance BE-16627.
摘要:
The present invention relates to a compound represented by the general formula (I): ##STR1## wherein R.sub.1 is a hydrogen atom, or ##STR2## and R.sub.2 is a hydrogen atom or OH and R.sub.2 is a hydrogen atom or a lower alkanoyl group, and an antifungal agent containing it as an active ingredient.
摘要:
The hydrogen separation device comprises a laminate formed by laminating and integrating a hydrogen separation layer, a mixed gas layer kept adjacent to one surface of the hydrogen separation layer and having a mixed gas flow path, and a transmitted gas layer kept adjacent to the other surface of the hydrogen separation layer and having a transmitted gas flow path, and a vessel containing the laminate therein and filled with a buffer gas, wherein a buffer space is provided between the laminate and the inner wall of the vessel in which a buffer gas can reach at least one end face of the laminate in the lamination direction, and wherein the pressure in the buffer space is equal to or higher than the higher one of the pressure in the mixed gas flow path and the pressure in the transmitted gas flow path.
摘要:
The present invention relates to a compound represented by general formula (I) or a pharmaceutically acceptable salt or ester thereof: ##STR1## wherein each of R.sup.1 and R.sup.2 is independently a hydrogen atom, a C.sub.1 -C.sub.16 alkyl group, a C.sub.2 -C.sub.10 alkenyl group, a C.sub.3 -C.sub.6 alkynyl group, a C.sub.6 -C.sub.12 aryl group, a C.sub.7 -C.sub.15 aralkyl group or a heterocyclic group which is not substituted, a C.sub.1 -C.sub.16 alkyl group, a C.sub.2 -C.sub.10 alkenyl group, a C.sub.3 -C.sub.6 alkynyl group, a C.sub.6 -C.sub.12 aryl group, a C.sub.7 -C.sub.15 aralkyl group or a heterocyclic group which has substituent(s), or a group represented by --Y--R.sup.3 (provided that when R.sup.2 is a hydrogen atom, R.sup.1 is not a methyl group or an acetyl group; when R.sup.2 is an acetyl group, R.sup.1 is not a methyl group), an antifungal agent containing it as an active ingredient and an antifungal composition containing it and an azole type antifungal agent.